Cargando…

The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest tumors, characterized by its aggressive tumor biology and poor prognosis. While immune checkpoint inhibitors (ICIs) play a major part in the treatment algorithm of various solid tumors, there is still no evidence of clinical benefit fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran, Linh Chi, Özdemir, Berna C., Berger, Martin D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609661/ https://www.ncbi.nlm.nih.gov/pubmed/37895882 http://dx.doi.org/10.3390/ph16101411

Ejemplares similares

Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma
por: Brown, Jason R., et al.
Publicado: (2021)

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
por: Gopalakrishnan, Dharmesh, et al.
Publicado: (2018)

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology
por: Özdemir, Berna C
Publicado: (2021)

The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex
por: Wahli, Murielle N., et al.
Publicado: (2022)

Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors—2020 Update
por: Jung, Gerhard, et al.
Publicado: (2020)

The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors
por: Alimonti, Paolo, et al.
Publicado: (2023)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

Aurora Kinase Inhibitors: Current Status and Outlook
por: Bavetsias, Vassilios, et al.
Publicado: (2015)

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
por: Fan, Jia-qiao, et al.
Publicado: (2020)

Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers
por: Eso, Yuji, et al.
Publicado: (2020)

Antithrombin Therapy: Current State and Future Outlook
por: Rodgers, George M., et al.
Publicado: (2023)

Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma
por: San-Román-Gil, María, et al.
Publicado: (2023)

Toxicity, disease management and outcome of treatment with immune checkpoint inhibitors by sex in patients with cancer and preexisting autoimmune disease
por: Liu, Michael, et al.
Publicado: (2023)

Fatal Immune Checkpoint Inhibitor-related Pancreatitis
por: Ueno, Masayuki, et al.
Publicado: (2021)

Acute cardiac manifestations under immune checkpoint inhibitors—beware of the obvious: a case report
por: Arangalage, Dimitri, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
por: Cefalo, Chiara Maria Assunta, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis
por: Pagan, Andrea, et al.
Publicado: (2020)

Two Types of Immune Checkpoint Inhibitor-related Pancreatitis
por: Ichiki, Tomoko, et al.
Publicado: (2021)

The outlook of rheumatological care in Africa: Current state, challenges, and recommendation
por: Nicholas, Aderinto, et al.
Publicado: (2022)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
por: Sivapiragasam, Abirami, et al.
Publicado: (2020)

Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2022)

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2023)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

Videolaparoscopic appendectomy: the current outlook
por: Hof, K. H. in’t
Publicado: (2007)

Videolaparoscopic appendectomy: the current outlook
por: Hof, K. H. in’t, et al.
Publicado: (2007)

Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
por: Zhang, Amy L., et al.
Publicado: (2021)

Pancreatic adverse events in patients treated with immune checkpoint inhibitors
por: Hana, Caroline, et al.
Publicado: (2023)

Immune checkpoint inhibitor-related pancreatitis: What is known and what is not
por: Jiang, Chunyan, et al.
Publicado: (2023)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Current state and outlook for drug repositioning anticipated in the field of ovarian cancer
por: Kobayashi, Yusuke, et al.
Publicado: (2018)

Conductive Scaffolds for Bone Tissue Engineering: Current State and Future Outlook
por: Dixon, Damion T., et al.
Publicado: (2021)

Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy
por: Johansen, Astrid Z., et al.
Publicado: (2023)

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
por: Chiang, Ryan S., et al.
Publicado: (2020)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
por: Passiglia, Francesco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l3h2c5ji9nupja74ahk7n2a838